Spaulding Clinical to Disrupt Cardiac Safety Industry with Latest Innovation at DIA 2016

West Bend, WI, June 25, 2016 --(PR.com)-- Spaulding Clinical Research, LLC, a global clinical pharmacology, cardiac safety and biometrics solutions provider, today announced that the Spaulding Electrocardiograph 2100iQ™ is to be exhibited at the Drug Information Association’s (DIA) 2016 conference.

The Spaulding 12-Lead ECG product line was originally launched in 2011 and is now in use in over 35 countries. The Spaulding Electrocardiograph 2100iQ has been optimized to visualize collected real-time digital ECG data via Bluetooth® using iOS™ 7+, Android™ 4.2+ and Windows™ 7+ devices. Data is wirelessly uploaded to the Spaulding webECG™ management cloud for Cardiologist over-reads and is designed to integrate with electronic medical records and clinical information management systems.

Features:

-Small (3.5 in), Lightweight (3.3 oz) Design for Easy Storage and Reduced Shipping Costs
-Single Button Operation for Ease of Use
-Protocol-Driven User Interface
-Multiple Protocol Support to Eliminate Need of Additional Equipment
-Stores up to 5 minutes of ECG data, Eliminates Need for Triplicate ECGs

“The Spaulding Electrocardiograph 2100iQ makes it logistically and financially feasible to collect very high-quality, centralized ECG data,” said Dr. Jay Mason, Chief Medical Officer. “This innovation in cardiac safety sets a new standard for data collection and gives Pharmaceutical Sponsors the ability to make earlier and better-informed drug development decisions.”

About Spaulding Clinical Research, LLC

Spaulding Clinical Research, LLC is a global CRO providing Phase I - IV drug development services to the biotechnology and pharmaceutical industries. Spaulding Clinical Research operates a 200-bed Clinical Pharmacology Unit, Cardiac Core Laboratory and provides full Biometrics/Scientific Affairs services.